실적분석 2026년 8월 5일

Recursion Pharmaceuticals ($RXRX) 2026 Q2 Earnings Analysis — Revenue Miss and After-Hours Weakness Despite Lower Cash Cost Guidance

Earnings Scorecard

Revenue: $7.7 million (approximately -60% year over year; consensus $11.96 million) ❌ Miss

EPS: GAAP loss per share -$0.25 (not directly comparable to the adjusted estimate of -$0.23 due to differing bases)

Guidance: Lowered — 2026 full-year cash operating cost outlook cut by $15 million, from $390 million to $375 million

Stock reaction: After-hours -8.50% ($3.03) — as of 08-05 21:04 KST

What Went Well

Genentech target option: The first validated target from the Roche/Genentech neuroscience collaboration has advanced into early discovery

Lower cost guidance: 2026 cash operating cost outlook reduced by $15 million to $375 million

Pipeline progress: Additional Phase 2 data for REC-4881 upcoming; REC-7735 IND clearance secured, with a Phase 1/2 trial slated for the second half

As a clinical-stage techbio company, Recursion's core value lies less in proprietary product sales than in collaboration milestones and validation of its discovery engine. The notable point this quarter was Genentech's exercise of the option on the first validated target from the neuroscience collaboration, advancing it into a joint early discovery program. Management framed this as early evidence that the AI-powered platform can identify and experimentally validate novel targets. Under the Roche/Genentech collaboration, the company has received cumulative upfront and milestone payments of $216 million, with significant potential milestone value per program across development, commercialization, and net sales stages.

Financially, the net loss narrowed to $131 million in 2026 Q2 from $171.9 million a year earlier, with R&D and SG&A expenses also declining. Management lowered its full-year cash operating cost guidance to reflect additional operating efficiencies and reaffirmed that its cash runway (without further financing) extends into early 2028 under current plans. Cash, cash equivalents, and restricted cash stood at $555.68 million at the end of June.

What Fell Short

Revenue miss: Total revenue of $7.7 million came in well below the $11.96 million estimate

Sharp year-over-year decline: Roughly 60% drop from $19.2 million a year earlier due to timing of collaboration revenue recognition

Persistent cash burn: Quarterly operating cash outflow of $105.9 million; cash balance declined versus the start of the year

This quarter's $7.7 million in total revenue fell well short of analyst expectations of $11.96 million. Management attributed the gap to the timing of Roche/Genentech-related revenue recognition, noting that the prior quarter had benefited from the completion of certain program stages, whereas this quarter did not. Because collaboration revenue tends to be lumpy depending on program progression, it is difficult to judge the value of the discovery engine from a single quarter's numbers — but the magnitude of the miss against expectations remains a drag.

Losses narrowed but remained in the $100 million range for the quarter, and operating cash outflows widened to $105.9 million from $76.4 million a year earlier. The prior-year comparison also benefited from a $28.6 million inflow related to a UK R&D tax credit. Cash and equivalents declined from $753.9 million at the start of the year to $555.68 million at the end of June, and with clinical and research costs continuing, future milestone inflows and cost discipline are points to monitor together.

What Management Said

CEO Najat Khan emphasized that the AI-powered platform is at an inflection point in converting proprietary data into potential first-in-class therapeutic opportunities, and cited the progression of the first novel neuroscience target from the Roche/Genentech collaboration into an early discovery program as an important validation case. The tone was that combining large-scale disease-relevant data, foundation models, and partnerships can reveal new biology in neuroscience, where novel targets have historically been difficult to identify through conventional means.

On guidance, rather than issuing fresh revenue or EPS outlooks, management put the message of a lower annual cash operating cost and a runway extending into early 2028 front and center. On the proprietary pipeline, the company previewed additional Phase 2 data for the familial adenomatous polyposis candidate REC-4881 at a November medical conference main session and signaled updates on the regulatory registration path in the second half. REC-7735 received IND clearance and is set to begin a Phase 1/2 trial in the second half. The market appeared more sensitive to the immediate revenue miss and the pace of cash burn than to the discovery platform and clinical narrative.

Market Reaction and Watchpoints

Given the lumpy, quarter-to-quarter collaboration revenue recognition characteristic of clinical-stage techbio companies, progress on the discovery engine alone did not appear sufficient to offset the revenue miss. The Genentech target option exercise and the lower cost guidance are positives for the longer-term story, but the short-term earnings axis has tilted toward the revenue miss, which naturally led to selling pressure in the more risk-averse after-hours session. The share price figures themselves are laid out in the scorecard, so the watchpoints going forward are whether the next cash inflow events and clinical milestones can reset the narrative.

Additional Phase 2 safety and efficacy data for REC-4881 at the November medical conference, along with the outcome of regulatory discussions on the registration pathway in the second half, will be pivotal for pipeline credibility.

The Phase 1/2 start of REC-7735 in the second half and progress on the Sanofi collaboration's development candidates and later-stage discovery milestones need to be confirmed.

Whether the company delivers against the $375 million full-year cash operating cost guidance and receives collaboration milestone inflows will determine whether the cash runway (into early 2028) is preserved.